---
title: "Obefazimod (ABX464) in Ulcerative colitis: Economic impact on families"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Economic impact on families. Topics: Caregiver burden, mental health, and work productivity: meta-analysis of 25 studies; Caregiver burden and lost productivity among 102 caregivers of adults with inflammatory bowel disease at a US center; Out-of-pocket costs and lost wages of patients with inflammatory bowel disease; Work impairment and estimated lost wages in employed US patients with moderate-to-severe ulcerative colitis; 2 further topics. 6 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description/economic-impact-on-families"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Economic impact on families

<a id="heading-2.2.1.8.3"></a>

## 2.2.1.8.3 Economic Impact of Ulcerative colitis on Families

<a id="topic-2.2.1.8.3-1"></a>

### Caregiver burden, mental health, and work productivity: meta-analysis of 25 studies

> “Out of 383 records, 25 studies met the inclusion criteria, with 12 eligible for meta-analysis. The pooled prevalence of caregiver burden was 470 per 1000 carers (95% CI: 390–560), depression at 370 per 1000, and anxiety at 400 per 1000. Loss of work productivity and activity impairment were reported in 290 and 300 per 1000 caregivers, respectively. Stress, reduced quality of life, and financial burden were also common.”
> “Only two studies assessed financial loss in caregivers for paediatric and adolescent population with IBD [32, 33]. Both studies provided absolute numbers of financial loss in caregivers as an estimate of annual productivity costs, which were calculated by the human capital approach.”

Source: [Dadoo et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13312674/)

<a id="topic-2.2.1.8.3-2"></a>

### Caregiver burden and lost productivity among 102 caregivers of adults with inflammatory bowel disease at a US center

> “One hundred two IBD patients and their respective caregiver were included. In total, 39% of IBD caregivers experienced burden. Caregivers with burden experienced significantly more absenteeism and presenteeism (65 and 85% respectively).”
> “Predictors of burden included race/ethnicity, history of fistulas, diagnosis of ulcerative colitis, higher caregiver education, and hours spent caregiving.”
> “The caregivers spent an average of 12 h (SD 25) per week on caregiving and had been caregiving for an average of 8.1 years (SD 8.5).”
> “The employment rate in the caregiver population was 72% (n = 73), of whom 38% (n = 28) experienced absenteeism within the last week, with a mean of 9% of work hours missed (SD 17%); 57% experienced presenteeism with a mean decrease of 22% in productivity at work (SD 30%).”

Source: [Zand et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7302133/)

<a id="topic-2.2.1.8.3-3"></a>

### Out-of-pocket costs and lost wages of patients with inflammatory bowel disease

> “Compared with non-IBD patients, IBD patients absorbed more than twice the out-of-pocket costs per year ($2213 vs $979), as shown in Figure 2B. Of note, this statistic does not include costs that IBD patients paid for insurance premiums (data not available) and thus likely represents an underestimate of the patient-responsible costs for health care (including IBD care). Patients with IBD also absorbed significantly higher wage-related opportunity loss based on yearly patient time costs, as shown in Figure 2C. Using the median wage, IBD patients’ lost wages were higher than the actual out-of-pocket costs on a per-year basis.”
> “Out-of-pocket and indirect costs of care reported in our analysis were likely substantial underestimates due to the data sets utilized in the analysis because the data did not include insurance premiums or other indirect costs such as actual wages lost, time for caregivers, or transportation required for health care services.”

Source: [Park et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7534391/)

<a id="topic-2.2.1.8.3-4"></a>

### Work impairment and estimated lost wages in employed US patients with moderate-to-severe ulcerative colitis

> “Patients with active disease in the US and EU5 reported the highest levels of presenteeism (adjusted means = 31.0 and 49.1%, respectively), overall work impairment (adjusted means = 34.5 and 54.4%), and activity impairment (adjusted means = 34.7 and 47.6%) (Figs. 4 and 5). Patients with active disease in the US had significantly higher levels of absenteeism than patients in remission (adjusted means = 9.2% vs. 2.0%, P < 0.05)”
> “Although a formal evaluation of indirect cost estimates is beyond the scope of this study, using a human capital approach, the levels of overall work impairment we observed would equate to $15,400 in lost wages per employed patient with UC per year in the US (based on annualized 2017 median weekly earnings from the US Bureau of Labor Statistics [19])”

Source: [Armuzzi et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6975026/)

<a id="topic-2.2.1.8.3-5"></a>

### Work absence and family decisions in the UC Narrative global survey

> “Overall, the majority (83%) of patients agreed that having UC impacted their work, with 74% of employed patients reporting work absence because of their UC and missing a mean of 8.1 working days (SD, 16.7) in the past 12 months because of their UC symptoms.”
> “However, 39% of patients had not told their employer about their UC diagnosis because of a fear of repercussions.”
> “More than one-third of patients (37%) reported that UC had influenced their decisions regarding family (including deciding not to have children, to have any more children, postponing having children, deciding to adopt, stopping treatment to start a family, or postponing/ending/avoiding romantic relationships).”

Source: [Dubinsky et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8528151/)

<a id="topic-2.2.1.8.3-6"></a>

### Effect of bowel urgency on work or school among US patients with moderate-to-severe ulcerative colitis

> “Of the patients who had ever experienced bowel urgency, 78.0% of US and 77.2% of European patients reported that it negatively affected work or school (Figure 3B).”

Source: [Travis et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11144997/)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
